Clinical Trial Update: Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity [Phase 3]

View source ↗

Summary

MET097 is being studied in a Phase 3 trial to evaluate efficacy and safety in adults with obesity/overweight, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• MET097

Snippet

Sponsor: Metsera, a wholly owned subsidiary of Pfizer | Conditions: Obesity and Overweight | Phase 3 | Status: RECRUITING